RE: More info regarding MediChem and RBS Invoice Finance facility11 Aug 2022 15:11
I am long Rev B
They ‘ paid ‘ £27M for the manufacturing plant but it’s instalments, my ready reckoner says they still have £4M a year to pay for the next few years
The ‘ owner ‘ Tom is on the BoD and is a major shareholder, hopefully he will take a payment plan.
The way it’s looking I feel someone will take out Rev B, there is no chance of a raise, there will be a floating charge on the £40M facility ex the factory which will have a separate single charge via Tom
The BoD will have their fiduciary duties to consider, it’s just at what price can they get as a going concern IF a they can’t finance ?
Although the RNS does say;
‘It should be noted the potential changes to the results for FY22 do not impact the net debt position previously notified of £21.2m as at 31 July 2022 and management reiterate they believe that the Group's £40m revolving credit facility provides sufficient liquidity for the future. Management also confirm that guidance for the year ending 28 February 2023, as set out in the announcement on 2 August 2022 remains unchanged’